![]() |
|
|
Vol. 281, Issue 1, 322-329, 1997
Departments of Pharmacology and Therapeutics (X.F.D., D.R.V.) and Medicine (S.M.), McGill University, Montreal, Quebec, Canada H3G 1Y6 and Department of Pediatrics and Pharmacology (S.C.), Sainte Justine Hospital Research Center, University of Montreal, Quebec, Canada H3T 1C5
| |
Abstract |
|---|
|
|
|---|
This study investigated the mechanism of the positive inotropic effects of class 1 antiarrhythmic agents using electrically stimulated right atria (sinoatrial node excised), left atria and right ventricles of rats. Quinidine, disopyramide and procainamide produced concentration-dependent positive inotropic effects on right and left atria; effects on the right atria were greater than on left atria. At concentration producing positive inotropic effects on atria, the contractions of right ventricles were slightly increased by quinidine, unaffected by disopyramide and decreased by procainamide. The positive inotropic effects of quinidine were inhibited by propranolol, reserpine and mecamylamine but not by cocaine, hexamethonium and d-tubocurarine; propranolol also antagonized the positive inotropic effects of disopyramide and procainamide. Bupivacaine, which like quinidine blocks transient outward potassium current, slightly increased the contractions of right atria but not of left atria and ventricles. The atrium-specific positive inotropic effects of quinidine were mimicked by atropine, pirenzepine and dimethylphenylpiperazinium but not by nicotine, cytisine and butyrylcholine; the effects of atropine, dimethylphenylpiperazinium and pirenzepine were also blocked by propranolol. Quinidine increased the release of norepinephrine from atria but not from the ventricles; this release was greater from the right than from the left atria. It is concluded that quinidine- and atropine-like agents exert atrium-specific positive inotropic effects by blocking muscarinic receptors and permitting a dominance of acetylcholine effects via a release of norepinephrine from sympathetic nerve terminals.
| |
Introduction |
|---|
|
|
|---|
Class 1 antiarrhythmic agents,
quinidine, disopyramide and procainamide modify myocardial refractory
period, conduction velocity and excitability by blocking sodium
channels (Roden, 1996
); in addition they all possess atropine-like
activity to varying degrees (Corr et al., 1978
; Mirro
et al., 1980
; Roden, 1996
). Quinidine also inhibits various
K+ currents (Imaizumi and Giles, 1987
; Snyders et
al., 1992
; Roden, 1996
). Quinidine is the oldest antiarrhythmic
agents. One of the problems in the clinical use of quinidine in atrial
flutter or fibrillation is the potential of increase in ventricular
rate because of a decrease in atrioventricular block presumably because of its atropine-like activity (Roden, 1996
).
In the course of using quinidine as a potassium channel blocker, we
observed that it produced positive inotropic effects on atrial but not
on ventricular preparations. A myocardial stimulant effects of
quinidine has been reported previously. For example, quinidine was
found to reverse the effects of vagal stimulation on the sinus rhythm
of cats (Dale, 1921
) and dogs (Lewis et al., 1921
) and it
was concluded by Dale (1921)
that the "partial or complete paralysis
of vagal action produced by quinidine is not due to an atropine-like
action." A later study identified the dependence of the accelerator
effects of quinidine on dog heart on norepinephrine (Roberts et
al., 1962
). However, the precise mechanism for the region-specific
positive inotropic effects of quinidine is not known.
All regions of the heart are sympathetically innervated; however,
cholinergic innervation is far more abundant in the atria than in the
ventricles (Burnstock, 1969
; Kent et al., 1974
). We postulated that a positive inotropic effect of quinidine on atria but
not on the ventricles might be related to its atropine-like action and
relatively abundant cholinergic innervation of the atria but not of the
ventricles. If so, endogenously released ACh might not be able to exert
a negative inotropic effect via muscarinic receptors in the presence of
quinidine but it might release endogenous norepinephrine from the
sympathetic nerve endings via nicotinic ACh receptors. If this
hypothesis was correct, a positive inotropic effect of quinidine will
be exerted indirectly via norepinephrine and other class 1 antiarrhythmic agents with significant atropine-like activity; as well,
atropine and other antimuscarinic agents should exert positive
inotropic effect on the atria but not on the ventricles. In our study
we tested this hypothesis using electrically stimulated left and right
atrial (devoid of sinus node) as well as right ventricular muscle
preparations from rats.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals. Cocaine hydrochloride was purchased from BDH, Toronto, Ontario, Canada. The following agents were purchased from Sigma Chemical Co., St. Louis, MO: atropine sulfate, bupivacaine hydrochloride, cytisine, dimethyl-4-phenylpiperazinium iodide, dihydroxybenzylamine, disopyramide phosphate, L-dopamine, L-epinephrine, hexamethonium bromide, mecamylamine hydrochloride, nicotine sulphate, L-norepinephrine, procainamide hydrochloride, propranolol hydrochloride, quinidine sulphate, reserpine, d-tubocurarine chloride, tyramine hydrochloride.
Animals. Male (250-350 g) Sprague-Dawley rats (Charles River, St. Constant, Quebec, Canada) were used according to a protocol of the McGill University Animal Care Committee. Animals were maintained at 23°C, 50 to 70% humidity and a 12-hr light-12-hr dark schedule (lights on 07.00-19.00 hr) and fed ad libitum rat food and tap water. To deplete endogenous norepinephrine, 5 mg/kg reserpine were injected i.p. 24 hr before animals were used for these studies. Rats were decapitated and hearts quickly removed and used for different experiments as described below.
Inotropic responses.
Left atrial, right atrial and right
ventricular strips were used to determine inotropic responses. Right
atria were excised so as to exclude the sinoatrial node; if right atria
exhibited spontaneous contractions, preparations were discarded. Right
ventricles were cut along their length into three identical pieces,
each approximately 3 × 10 mm; one or two of these strips were
used. Atrial and ventricular preparations were set up in tissue baths at 32°C in Krebs buffer of the following composition (mM): NaCl 117, KCl 4.7, CaCl2 1.8, MgSO4 1.18, KH2PO4 1.2, NaHCO3 25, dextrose 11 and EDTA 0.03 (Varma and Yue, 1986
; Deng et al., 1996
). The buffer was gassed with a mixture of 95% O2 and 5%
CO2. Preparation were stimulated at 1 Hz, 5 msec pulse
duration and 1.5 times the threshold voltage (20-30 V). In each
preparation, the tension was adjusted to yield maximal basal isometric
contractions. The applied tensions to the atrial and ventricular
preparations were approximately 0.5 and 1.0 g, respectively. The
tension was recorded by means of Grass force-displacement transducers
(FT03C) on a Grass polygraph (Quincy, MA). Preparations were allowed to
equilibrate for 45 to 60 min with changes in Krebs buffer every 15 min.
Inotropic effects of various agents were determined by cumulative
increases in their concentrations.
Effect of quinidine on catecholamine release. Right and left atrial strips were set up as described above but in 20 ml buffer. Preparations were equilibrated for 45 min and the buffer was changed; 1 µM cocaine was present throughout to inhibit uptake of released norepinephrine. A 15-min sample of the buffer (20 ml) was collected in 50 ml polypropylene tubes and the pH of the buffer immediately reduced to 5 by adding predetermined volume of 1 M HCl. The buffer was changed and 1 µM quinidine was added and a 15-min sample of the buffer was collected and acidified as before; this process was repeated with increasing concentrations (3, 30, 300 µM) of quinidine; after the last buffer collection, the wet weights of tissues were recorded. The release of catecholamines from right ventricular strips was determined following a single 30 µM concentration of quinidine. Buffer samples were stored at -20°C for the assay of catecholamines within less than 1 wk.
Epinephrine, norepinephrine and dopamine were assayed by high-pressure liquid chromatography (Waters Pump model 510) using electrochemical detectors (Waters model 460, Milford, MA) as described (Shohami et al., 1983Statistics. Data were compared by Student's t test for unpaired or paired data and a P < .05 was assumed to denote significant differences. Data are presented as mean ± S.E.M.
| |
Results |
|---|
|
|
|---|
Basal contractions and effects of pretreatments. Basal contractions of all the right atria, left atria and right ventricles used in this study were 330 ± 15 mg (n = 98), 421 ± 17 mg (n = 100) and 651 ± 38 mg (n = 53), respectively, and significantly (P < .05) different from each other. However, there were marked variations in basal contractions so that contractions of left and right atria used to test different agents did not always differ significantly (table 1). The basal contractions of right and left atria from reserpine treated rats were 290 ± 23 mg (n = 14) and 361 ± 31 mg (n = 12), respectively, and did not differ significantly from the corresponding basal contractions of these tissues (right atria 330 ± 15 mg, n = 98; left atria 421 ± 17 mg, n = 100) from untreated animals. Propranolol (1 µM) caused a significant decrease in basal contractions of right and left atria to 76 ± 4% (n = 14) and 84 ± 6% (n = 6), respectively. Cocaine (1 µM) increased the basal contractions of right atria from 300 ± 35 to 362 ± 34 mg and of left atria from 410 ± 39 to 475 ± 43 mg (n = 6); the increase was not significant. Mecamylamine, d-tubocurarine and hexamethonium did not exert any apparent effects on the contractions of right or left atria. None of the treatments altered stimulus parameters.
|
Inotropic responses to class 1 antiarrhythmic agents and
bupivacaine.
Quinidine (fig. 1a), disopyramide
(fig. 1b) and procainamide (fig. 1c) produced concentration-dependent
increase in the contractile force of right and left atria (table
1); effects became apparent within 1 to 2 min and reached a peak in
5 to 10 min. The concentration response-curves were relatively steep
and the difference between the minimal and maximal concentrations were
usually 10-fold. Contractions returned to basal levels after a 60- to
90-min period of repeated wash; a second concentration-response curve
to quinidine did not reveal any apparent "tachyphylaxis." The
contractions of right ventricles were slightly but significantly
(P < .05) increased by quinidine, not modified by disopyramide
and significantly (P < .05) decreased by procainamide (table 1).
Bupivacaine exerted a slight but significant (P < .05) positive
inotropic effect on the right atria but significantly (P < .05)
inhibited the contractions of the left atria and the right ventricles
(fig. 1d; table 1).
|
Inotropic response to isoproterenol. As with the class 1 antiarrhythmic agents, isoproterenol also produced greater maximal positive inotropic effect on the right atria than on the left atria; as expected isoproterenol increased the force of contractions of right ventricular strips (table 1). Indeed, of all the agents studied (isoproterenol, quinidine, disopyramide, procainamide, bupivacaine, atropine, pirenzepine, nicotine, DMPP, cytisine, butyrylcholine and physostigmine), only isoproterenol and to a much smaller extent quinidine exerted positive inotropic effect on right ventricular strips (table 1).
Effects of reserpine and propranolol on responses to quinidine and
disopyramide.
As stated above, pretreatment with reserpine did not
produce significant effects on the basal contractions of atrial
preparations. However, reserpine pretreatment significantly decreased
the positive inotropic effects of both quinidine (fig.
2a) and disopyramide (fig. 2b).
|
Effects of cholinergic and anticholinergic agents on myocardial
contractions.
Atropine (fig. 3a), pirenzepine (fig.
3b) and DMPP (fig. 3c) produced a concentration-dependent increase in
contractions of the left and right atria but not of the right
ventricles; the positive inotropic effects on the right atria were
greater than on the left atria. Nicotine (fig. 3d), cytisine and
butyrylcholine did not produce positive inotropic effects on any of the
myocardial preparations (table 1). Physostigmine and butyrylcholine
decreased the contractions of atria but exerted little effect on the
contractions of the right ventricles (table 1).
|
Antagonism of the positive inotropic effects of atropine, DMPP and
pirenzepine by propranolol.
Propranolol (1 µM) antagonized the
positive inotropic effects of atropine (fig. 4a) and
DMPP (fig. 4b) and significantly (P < .01) decreased the maximal
effects of both these agents. For example, the maximal contractile
force of right atria after 1 µM atropine was 197 ± 26% of the
basal in the absence and 125 ± 13% of the basal in the presence
of 1 µM propranolol (n = 6); similarly, the maximal
contractile force of right atria after 30 µM DMPP was 194 ± 13% of the basal in the absence and 154 ± 8% of the basal in
the presence of propranolol (n = 5). The effect of
propranolol on the concentration-response curve to pirenzepine was not
studied; however, the peak response to pirenzepine was significantly
(P < .01) reduced from 218 ± 23% of the basal to 101 ± 5% of the basal after the addition of 1 µM propranolol
(n = 5).
|
Effects of cocaine and nicotinic ACh receptors antagonists on
inotropic responses to quinidine.
Cocaine (1 µM) cause a slight
but insignificant increase in basal contractions and did not inhibit
the positive inotropic effects of quinidine (fig. 5a);
at this concentration cocaine markedly reduced the positive inotropic
effects of tyramine (data not shown).
|
Effects of quinidine on catecholamine release.
Both atria and
ventricles released norepinephrine, epinephrine as well as dopamine in
the absence of quinidine (basal release); the release of norepinephrine
was greater than that of the other two catecholamines (fig.
6). Quinidine caused a concentration-dependent increase
in norepinephrine release from both the right (fig. 6a) and left (fig.
6b) atria; however, the release of norepinephrine declined to basal
levels following the highest concentration (300 µM) of quinidine
tested. Quinidine did not significantly increase the release of
epinephrine and dopamine. At 30 µM concentration, which caused
maximal release of norepinephrine from both the left and right atria,
quinidine did not cause a significant release of any of the
catecholamines from right ventricular strips (fig. 6c).
|
| |
Discussion |
|---|
|
|
|---|
Diverse agents can cause myocardial depression and this is often
described as "quinidine-like" effect. Therefore a positive inotropic activity of quinidine as found in our study might seem unusual. However, a stimulant effect of quinidine on cardiac rate (Dale, 1921
; Lewis et al., 1921
; Roberts et al.,
1962
) and a positive inotropic effect of quinidine on atria but not on
ventricular muscles of guinea pigs (Nawrath, 1981
) has been previously
reported. Our study confirms these observations and attempts to
identify the underlying mechanisms. Specifically we tested the
hypothesis that the atrium-specific positive inotropic effects of
quinidine are related to its known atropine-like activity (Mirro
et al., 1980
; Roden, 1996
) and to the presence of abundant
cholinergic plus noradrenergic innervation of atria (Burnstock, 1969
)
but sparse cholinergic innervation of the ventricles (Kent et
al., 1974
). A negative inotropic effect of physostigmine on the
atria but not on the ventricles as found in our study (table 1) are consistent with the data that ventricles are poorly innervated by
cholinergic nerves.
This study demonstrates that quinidine and the other class 1 antiarrhythmic agents, disopyramide and procainamide, significantly increase the force of contraction of atria at concentrations within the therapeutic range; the contractions of ventricles were slightly increased by quinidine, virtually unaffected by disopyramide and consistently decreased by procainamide (fig. 1; table 1). However, high concentrations of quinidine (100 µM) and procainamide (10 mM) decreased the contractile force of atria as well; indeed quinidine slightly decreased the contractions of atria even at lower concentrations (1-3 µM) after the blockade of beta adrenoceptors with propranolol. It would thus appear that the positive inotropic effects determined in this study reflect the arithmetic sum of a stimulant and depressant activity with the former being dominant at low and the latter at high concentrations of the drug.
The quantitative differences between the positive inotropic efficacies
of quinidine, disopyramide and procainamide most probably relate to
their relative ACh muscarinic receptor blocking potencies with
quinidine and disopyramide being more potent than procainamide (Mirro
et al., 1980
; Roden, 1996
). The importance of antimuscarinic activity in the positive inotropic effects of class 1 antiarrhythmic agents is strongly supported by the observation that atropine and
pirenzepine mimicked the effects of these agents (fig. 3). Pirenzepine
is a selective M1 ACh receptor antagonist at low and M2 receptor antagonist at high concentrations and the heart
contains low affinity muscarinic receptors of the M2 type
(Hammer et al., 1980
; Goyal, 1989
). The positive inotropic
effects of both atropine and pirenzepine were observed at a relatively
high concentration range (0.1-10 µM) and pirenzepine was
approximately 10-fold less potent than atropine (table 1); this is
compatible with their relative M2 ACh receptor blocking
potencies in atria (van Charldorp and van Zwieten, 1989).
Our data suggest that the positive inotropic effects of quinidine are
produced indirectly by a release of norepinephrine; this inference is
supported by two sets of observations. First, quinidine caused a
concentration-dependent release of norepinephrine from both the right
and left atria but not the ventricles and the maximal release coincided
with its maximal positive inotropic effects (fig. 6). However, the
positive inotropic effects of quinidine cannot be quantitatively
explained on the basis of the net release of norepinephrine as measured
in this study; it is reasonable to assume that a significantly higher
concentration of neuronally released norepinephrine is delivered to the
receptors than can be quantified by the technique used in this study.
Second, the positive inotropic effects of quinidine were antagonized by
propranolol and inhibited by pretreatment of rats with reserpine (fig.
2). Our inference is in conformity with an earlier study, which also suggested the role of sympathetic nervous system in the cardiac stimulant effect of quinidine in dogs (Roberts et al.,
1962
). Because quinidine, disopyramide and procainamide as well as
atropine and pirenzepine produced little or no positive inotropic
effect on ventricles (figs. 1 and 2), it is unlikely that their effects were mediated by a direct activation of adrenoceptors; indeed both
quinidine (Roden, 1996
) and atropine (Varma and Yue, 1986
) possess
antiadrenergic properties. A greater positive inotropic effect of these
agents on the right than on the left atria seems to be due to a greater
release (fig. 6a, b) as well as effect of norepinephrine in the former
than in the latter tissue. Because isoproterenol also caused a greater
increase in the force of contractions of the right than of the left
atria (table 1), it would seem that the differences in the responses of
the right and left atria are also related to the relative roles of
beta adrenoceptors in the two organs.
Quinidine blocks several potassium currents (Roden, 1996
) including the
transient outward K+ current (Ito) (Imaizumi
and Giles, 1987
; Snyders et al., 1992
) and prolongs action
potential duration (Nawrath, 1981
). It is thus possible that the
positive inotropic activity of quinidine was partly caused by potassium
channel blockade; a slight increase in the force of contractions of
ventricles by quinidine and a lesser attenuation by reserpine of the
effects of quinidine than of disopyramide support this possibility. It
is possible that disopyramide, procainamide and atropine also block
potassium channels although we are not aware of any such reports; if so
the positive inotropic effects of these agents could also have been
contributed by potassium channel blockade. As well, atropine could
prolong atrial refractory period by its antimuscarinic action.
Notwithstanding these possibilities, overall data of this study suggest
that potassium channel blockade is not central to the positive
inotropic activities of quinidine- and atropine-like agents. Such
marked disparity between the positive inotropic efficacy of quinidine
on the atria and ventricles and significant inhibition of its effects
by propranolol and reserpine suggest that the major mechanism of its
positive inotropic activity is the release of norepinephrine. The data with bupivacaine lend support to the inference that the major effects
of quinidine are exerted through a release of norepinephrine. Bupivacaine is very similar to quinidine as a blocker of transient outward K+ current (Courtney and Kendig, 1988
; Castle,
1990
); however, its positive inotropic effect on the right atria were
significantly less than that of quinidine and it did not increase the
force of contractions of the left atrial preparations.
This study provides strong evidence that the positive inotropic effects
of quinidine are produced indirectly via a release of norepinephrine.
However, the mechanisms of the release of norepinephrine by quinidine
is not quite clear from our data. It is unlikely that quinidine
directly releases norepinephrine from sympathetic nerve endings like
tyramine (Potter and Axelrod, 1963
); if it did so, one would expect
quinidine to also exert a positive inotropic effects on the ventricles
such as tyramine but this was not the case. Also, cocaine that inhibits
the effects of indirectly acting sympathomimetic amines (Trendelenburg,
1966
), did not inhibit the positive inotropic effects of quinidine.
Indeed, quinidine-induced release of norepinephrine was measured in the
presence of cocaine. Our data suggest that the release of
norepinephrine by quinidine is mediated by ACh. Whether or not
quinidine increases the release of ACh is not clear from our studies
but atropine can release ACh (MacIntosh and Oborin, 1953; Goyal, 1989
)
and other atropine-like drugs such as class 1 antiarrhythmic agents
might also do so. It can thus be surmised that the released ACh
(enhanced or basal) acts on adrenergic nerve terminals to release
norepinephrine. This suggestion is supported by the observation that
quinidine increased the release of norepinephrine from atria but not
ventricles (fig. 6). The inability of quinidine to release
norepinephrine from the ventricles can be explained by an absence of
abundant cholinergic innervation of the ventricles (Burnstock, 1969
).
This inference is also consistent with the results of functional
studies that quinidine, atropine and other agents caused little or no increase in the contractile force of ventricles but produced a significant positive inotropic effect on the atria.
Assuming that ACh causes the release of norepinephrine from atrial
adrenergic nerves, our data provide indirect evidence that this
involves an unusual subtype of nAChR. For example, atrial contractions
were not increased by nicotinic agents nicotine, cytisine and
butyrylcholine. The inotropic effects of quinidine were not antagonized
by hexamethonium and d-tubocurarine but inhibited by
mecamylamine; mecamylamine is known to differ in certain respects from
other nAChR antagonists (Bertrand et al., 1990
). In other words, the indirect action of quinidine could neither be mimicked by
classical nAChR agonists nor blocked by conventional antagonists. However, DMPP very closely mimicked the effects of quinidine; it
exerted positive inotropic effects on the atria but not on the
ventricles and its effects on the atria were blocked by propranolol suggesting that the increase in atrial contractions was caused by
norepinephrine. These data are very similar to an earlier study that
found that DMPP exerted a stimulant effect on rat atria, which was
blocked by bretylium but not by hexamethonium (Chiang and Leaders,
1965
).
Taken together data of this study suggest that the positive inotropic
effects of various quinidine- and atropine-like agents are caused by a
single mechanism that involves a release of norepinephrine from
adrenergic nerve terminals by ACh acting on nAChR; these nAChR are
responsive to DMPP but not to nicotine and cytisine. Indeed nAChR with
3
2 combination have been found to be equally sensitive to ACh and
DMPP, much less sensitive to nicotine and virtually insensitive to
cytisine (Luetje and Patrick, 1991
); our data provide pharmacological
evidence for the presence of such nicotinic receptors in the atria of
rats. Most probably our assay system (inotropic response) is not
sensitive enough to demonstrate a weak positive inotropic response to
nicotine. At the same time, the inference drawn by us implies that
these nAChR with
3
2 combination are unique to sympathetic nerve
terminal in the atria and are not sufficiently expressed in the
ventricles.
In conclusion our study demonstrates that cholinergic innervation of
the atria and blockade of ACh muscarinic receptors are critical for the
positive inotropic activity of quinidine. The blockade of muscarinic
receptors is necessary to prevent the negative inotropic effect of ACh
and cholinergic innervation is necessary for the ACh-mediated release
of norepinephrine. In short, the atria-specific positive inotropic
effects of class 1 antiarrhythmic and atropine-like agents are caused
by ACh-mediated norepinephrine release from adrenergic nerve terminals
via nAChR responsive to DMPP but not to nicotine and cytisine (possibly
nAChR with
3
2 combination). If the data derived from rats reflect
events in humans, the propensity of quinidine to decrease
atrioventricular block and increase ventricular rate during atrial
flutter or fibrillation, might not be entirely due to its direct
antimuscarinic activity but also contributed by a release of
norepinephrine. Also, the high risk of ventricular fibrillation after
the clinical use of atropine to treat bradycardia (Massumi et
al., 1972
; Richman, 1974
) or in animal experiments (Corr and
Gillis, 1974
) might in part be contributed by a release of
norepinephrine.
| |
Acknowledgment |
|---|
The authors acknowledge the meticulous technical help of Ms Iona Sanoc in the assay of catecholamines.
| |
Footnotes |
|---|
Accepted for publication December 23, 1996.
Received for publication April 30, 1996.
1 This study was supported by a grant from Quebec Heart and Stroke Foundation.
Send reprint requests to: Dr. D. R. Varma, Department of Pharmacology and Therapeutics, McGill University, 3655 Drummond Street, Montreal, Quebec, Canada H3G 1Y6.
| |
Abbreviations |
|---|
ACh, acetylcholine; DA, dopamine; Epi, epinephrine; NE, norepinephrine; DMPP, dimethylphenylpiperazinium; nAChR, nicotinic acetylcholine receptors; RA, right atria; LA, left atria; RV, right ventricles; EDTA, ethylenediamine tetraacetate; pD2, negative log of the molar concentration of drugs producing 50% of the maximal effect.
| |
References |
|---|
|
|
|---|
- and
-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors.
J. Neurosci.
11: 837-845, 1991[Abstract].This article has been cited by other articles:
![]() |
G. N. Hendy, T. Li, M. Girard, R. C. Feldstein, S. Mulay, R. Desjardins, R. Day, A. C. Karaplis, M. L. Tremblay, and L. Canaff Targeted Ablation of the Chromogranin A (Chga) Gene: Normal Neuroendocrine Dense-Core Secretory Granules and Increased Expression of Other Granins Mol. Endocrinol., August 1, 2006; 20(8): 1935 - 1947. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||